Pluri (PLUR) Interest & Investment Income (2015 - 2023)
Pluri (PLUR) posted quarterly Interest & Investment Income of $781000.0 for Q2 2023, up 14.01% year-over-year from $685000.0 in Q2 2022, and up 218.69% quarter-over-quarter from -$658000.0 in Q1 2023.
Pluri (PLUR) Interest & Investment Income (2015 - 2023) Analysis & Trends
Pluri (PLUR) has reported Interest & Investment Income for 8 consecutive years, with $781000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Interest & Investment Income rose 14.01% year-over-year to $781000.0; the TTM figure through Jun 2023 stood at -$798000.0 (down 172.15% YoY), while the FY2023 annual figure was -$798000.0, down 172.15% from the prior year.
- Interest & Investment Income grew to $781000.0 in Q2 2023 per PLUR's latest filing, from -$658000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $781000.0 in Q2 2023 and bottomed at -$1.6 million in Q4 2022.
- Historically, Interest & Investment Income has averaged $91750.0 across 5 years, with a median of $76500.0 in 2019.
- Annual changes were most pronounced in 2020 — Interest & Investment Income surged 26100.0% — and 2022, when it tumbled 986.21%.
- Pluri's Interest & Investment Income stood at -$2000.0 in 2019, then soared by 26100.0% to $520000.0 in 2020, then slumped by 127.88% to -$145000.0 in 2021, then sank by 986.21% to -$1.6 million in 2022, then surged by 149.59% to $781000.0 in 2023.
- Business Quant data shows PLUR's Interest & Investment Income at $781000.0 in Q2 2023, -$658000.0 in Q1 2023, and -$1.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 781,000.00 |
| Mar 31, 2023 | -658,000.00 |
| Dec 31, 2022 | -1.58 Mn |
| Sep 30, 2022 | 654,000.00 |
| Jun 30, 2022 | 685,000.00 |
| Mar 31, 2022 | 557,000.00 |
| Dec 31, 2021 | -145,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 97,000.00 |
| Mar 31, 2021 | -29,000.00 |
| Dec 31, 2020 | 520,000.00 |
| Sep 30, 2020 | 248,000.00 |
| Jun 30, 2020 | 378,000.00 |
| Mar 31, 2020 | -108,000.00 |
| Dec 31, 2019 | -2,000.00 |
| Sep 30, 2019 | 56,000.00 |
| Sep 30, 2017 | -1.13 Mn |
| Jun 30, 2017 | 933,000.00 |
| Mar 31, 2017 | 990,000.00 |
| Dec 31, 2016 | -1.59 Mn |